Purines, purinergic receptors, and cancer

Cancer Research

Volumn 72, Issue 21, 2012, Pages 5441-5447

  Di Virgilio, Francesco ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE; ADENOSINE DEAMINASE; ADENOSINE TRIPHOSPHATE; CD39 ANTIGEN; LUCIFERASE; NUCLEOSIDE DIPHOSPHATE KINASE; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; PURINE DERIVATIVE; PURINERGIC P2X4 RECEPTOR; PURINERGIC P2X7 RECEPTOR; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y11 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; PURINERGIC P2Y2 RECEPTOR; PURINERGIC P2Y4 RECEPTOR; PURINERGIC P2Y6 RECEPTOR; PURINERGIC RECEPTOR;

ANTIGEN PRESENTATION; BINDING AFFINITY; CELL DIFFERENTIATION; CELL MEMBRANE; CELL METABOLISM; CELL PROLIFERATION; CELLULAR IMMUNITY; CYTOKINE RELEASE; DENDRITIC CELL; ENZYME DEGRADATION; GENE SILENCING; HUMAN; HYDROLYSIS; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TH1 CELL; THROMBOCYTE AGGREGATION; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UPREGULATION;

ANIMALS; HUMANS; NEOPLASMS; PURINES; RECEPTORS, PURINERGIC;

EID: 84868248487     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1600     Document Type: Review

References (63)

1. Lohmann K. Uber die pyrophosphatfraktion im muskel. Naturwis-senschaften 1929;17:624-5.
2. Drury AN, Szent-Gyorgyi A. The physiological activity of adenine compoundswith especial referencetotheiraction upon themamma-ian heart. J Physiol 1929;68:213-37.
3. Berne RM, Rubio R. Adenine nucleotide metabolism in the heart. Circ Res 1974;35[Suppl 3]:109-20.
4. Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 2007;14:1315-23.
5. Burnstock G. Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol Rev 2006;58:58-86.
6. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Phar-macol Rev 1998;50:413-92.
7. Gessi S, Merighi S, Sacchetto V, Simioni C, Borea PA. Adenosine receptors and cancer. Biochim Biophys Acta 2011;1808: 1400-12.
8. Von Kugelgen I, Harden TK. Molecular pharmacology, physiology, and structure of the P2Y receptors. Adv Pharmacol 2011;61: 373-415.
9. Coddou C, Yan Z, Obsil T, Huidobro-Toro JP, Stojilkovic SS. Activation and regulation of purinergic P2X receptor channels. Pharmacol Rev 2011;63:641-83.
10. Compan V, Ulmann L, Stelmashenko O, Chemin J, Chaumont S, Rassendren F. P2X2 and P2X5 subunits define a new hetero-meric receptor with P2X7-like properties. J Neurosci 2012;32: 4284-96.
11. North RA. Molecular physiology of P2X receptors. Physiol Rev 2002;82:1013-67.
12. Ferrari D, Pizzirani C, Adinolfi E, Forchap S, Sitta B, Turchet L, et al.The antibiotic polymyxin B modulates P2X7 receptorfunction. J Immunol 2004;173:4652-60.
13. Kim M, Jiang LH, Wilson HL, North RA, Surprenant A. Proteomic and functional evidence for a P2X7 receptor signalling complex. EMBO J 2001;20:6347-58.
14. Di Virgilio F, Chiozzi P, Ferrari D, Falzoni S, Sanz JM, Morelli A, et al. Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood 2001;97:587-600.
15. Ferrari D, Pizzirani C, Adinolfi E, Lemoli RM, Curti A, Idzko M, et al. The P2X7 receptor: a key player in IL-1 processing and release. J Immunol 2006;176:3877-83.
16. Schenk U, Frascoli M, Proietti M, Geffers R, Traggiai E, Buer J, et al. ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. Sci Signal 2011;4:ra12.
17. Junger WG. Immunecell regulation byautocrinepurinergicsignalling. Nat Rev Immunol 2011;11:201-12.
18. Gachet C. P2 receptors, platelet function and pharmacological impli-cations. Thromb Haemost 2008;99:466-72.
19. Baroni M, Pizzirani C, Pinotti M, Ferrari D, Adinolfi E, Calzavarini S, et al. Stimulation of P2 (P2X7) receptors in human dendriticcellsinducesthe release of tissue factor-bearing microparticles. FASEB J 2007;21: 1926-33.
20. Sichardt K, Nieber K. Adenosine A(1) receptor: Functional receptor-receptor interactions in the brain. Purinergic Signal 2007;3: 285-98.
21. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15:1170-8.
22. Yegutkin GG. Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim Bio-phys Acta 2008;1783:673-94.
23. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmacol 2000;362: 299-309.
24. Pellegatti P, Falzoni S, Pinton P, Rizzuto R, Di Virgilio F. A novel recombinant plasma membrane-targeted luciferase reveals a new pathway for ATP secretion. Mol Biol Cell 2005;16:3659-65.
25. Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F. Increased level ofextracellular ATP at tumorsites: in vivo imaging with plasma membrane luciferase. PLo S ONE 2008;3: e2599.
26. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011;334: 1573-7.
27. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011;8: 151-60.
28. Aymeric L, Apetoh L, Ghiringhelli F, Tesniere A, Martins I, Kroemer G, et al. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res 2010;70: 855-8.
29. Di Virgilio F, Boeynaems JM, Robson SC. Extracellular nucleotides as negative modulators of immunity. Curr Opin Pharmacol 2009;9: 507-13.
30. Blay J, White TD, Hoskin DW. The extracellular fluid of solid carcino-mas contains immunosuppressive concentrations of adenosine. Can-cer Res 1997;57:2602-5.
31. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK, et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A 2006;103:13132-7.
32. Mac Kenzie WM, Hoskin DW, Blay J.Adenosine in hibits the adhesion of anti-CD3-activated killer lymphocytes to adenocarcinoma cells through an A3 receptor. Cancer Res 1994;54:3521-6.
33. Hoskin DW, Butler JJ, Drapeau D, Haeryfar SM, Blay J.Adenosineacts through an A3 receptorto prevent the induction of murine anti-CD3-activated killer T cells. Int J Cancer 2002;99:386-95.
34. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, et al. Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithe-lia. J Clin Invest 2002;110:993-1002.
35. Eltzschig HK, Kohler D, Eckle T, Kong T, Robson SC, Colgan SP. Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. Blood 2009;113:224-32.
36. Braganhol E, Morrone FB, Bernardi A, Huppes D, Meurer L, Edelweiss MI, et al. Selective NTPDase2 expression modulates in vivo rat glioma growth. Cancer Sci 2009;100:1434-42.
37. Feng L, Sun X, Csizmadia E, Han L, Bian S, Murakami T, et al. Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate. Neoplasia 2011; 13:206-16.
38. Kunzli BM, Bernlochner MI, Rath S, Kaser S, Csizmadia E, Enjyoji K, et al. Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer. Purinergic Signal 2011;7: 231-41.
39. Stagg J, Divisekera U, Mc Laughlin N, Sharkey J, Pommey S, Denoyer D, et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A 2010;107: 1547-52.
40. Stagg J, Divisekera U, Duret H, Sparwasser T, Teng MW, Darcy PK, et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res 2011;71: 2892-900.
41. Stagg J, Beavis PA, Divisekera U, Liu MC, Moller A, Darcy PK, et al. CD73-deficient mice are resistant to carcinogenesis. Cancer Res 2012;72:2190-6.
42. Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TR. T regulatory and primed uncommitted CD4 Tcells express CD73, which suppresses effector CD4 T cells by converting 5'-adenosine mono-phosphate to adenosine. J Immunol 2006;177:6780-6.
43. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory Tcellsmediatesimmunesuppression.JExp Med2007;204: 1257-65.
44. +; Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007;110:1225-32.
45. Chalmin F, Mignot G, Bruchard M, Chevriaux A, Vegran F, Hichami A, et al. Stat3 and Gfi-1 transcription factors control Th17 cell immuno-suppressive activity via the regulation of ectonucleotidaseexpression. Immunity 2012;36:362-73.
46. Pro B, Dang NH. CD26/dipeptidyl peptidase IVand its role in cancer. Histol Histopathol 2004;19:1345-51.
47. Di Virgilio F, Ferrari D, Adinolfi E. P2X7: a growth-promoting receptor-mplications for cancer. Purinergic Signal 2009;5:251-6.
48. Di Virgilio F, Chiozzi P, Falzoni S, Ferrari D, Sanz JM, Venketaraman V, et al. Cytolytic P2X purinoceptors. Cell Death Differ 1998;5: 191-9.
49. Adinolfi E, Callegari MG, Ferrari D, Bolognesi C, Minelli M, Wieck-owski MR, et al. Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. Mol Biol Cell 2005;16: 3260-72.
50. Adinolfi E, Cirillo M, Woltersdorf R, Falzoni S, Chiozzi P, Pellegatti P, et al. Trophic activity of a naturally occurring truncated isoform of the P2X7 receptor. FASEB J 2010;24:3393-404.
51. Adinolfi E, Raffaghello L, Giuliani AL, Cavazzini L, Capece M, Chiozzi P, et al. Expression ofthe P2X7 receptor in creases in vivo tumor growth. Cancer Res. 2012;72:2957-69.
52. Jelassi B, Chantome A, Alcaraz-Pérez F, Baroja-Mazo A, Cayuela ML, Pelegrin P, et al. P2X7 receptor activation enhances SK3 channels-and cystein cathepsin-dependent cancer cells invasiveness. Onco-gene 2011;30:2108-22.
53. Gu BJ, Wiley JS. Rapid ATP-induced release of matrix metalloprotei-nase 9 is mediated by the P2X7 receptor. Blood 2006;107:4946-53.
54. Morrone FB, Oliveira DL, Gamermann P, Stella J, Wofchuk S, Wink MR, et al. In vivo glioblastoma growth is reduced by apyrase activity in a rat glioma model. BMC Cancer 2006;6:226.
55. Fishman P, Bar-Yehuda S, Madi L, Cohn I. A3 adenosine recep-tor as a target for cancer therapy. Anticancer Drugs 2002;13: 437-43.
56. Sauer AV, Brigida I, Carriglio N, Hernandez RJ, Scaramuzza S, Clavenna D, et al. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell func-tion and autoimmunity in ADA-deficient SCID. Blood 2012;119: 1428-39.
57. White N, Burnstock G. P2 receptors and cancer. Trends Pharmacol Sci 2006;27:211-7.
58. Wang Q, Wang L, Feng YH, Li X, Zeng R, Gorodeski GI. P2X7 receptor-mediated apoptosis of human cervical epithelial cells. Am J Physiol Cell Physiol 2004;287:C1349-58.
59. Fu W, Mc Cormick T, Qi X, Luo L, Zhou L, Li X, et al. Activation of P2X7-mediated apoptosis Inhibits DMBA/TPA-induced formation of skin papillomas and cancer in mice. BMC Cancer 2009;9:114.
60. Roger S, Pelegrin P. P2X7 receptor antagonism in the treatment of cancers. Expert Opin Investig Drugs 2011;20:875-80.
61. Agteresch HJ, Dagnelie PC, van der Gaast A, Stijnen T, Wilson JH. Randomized clinical trial ofadenosine5'-triphosphate in patientswith advanced non-small-cell lung cancer. J Natl Cancer Inst 2000;92: 321-8.
62. Beijer S, Hupperets PS, van den Borne BE, Eussen SR, van Henten AM, van den Beuken-van Everdingen M, et al. Effect of adenosine 5'-triphosphate infusions on the nutritional status and survival of preterminal cancer patients. Anticancer Drugs 2009; 20:625-33.
63. Varani K, Maniero S, Vincenzi F, Targa M, Stefanelli A, Manis-calco P, et al. A3 receptors are overexpressed in pleura from patients with mesothelioma and reduce cell growth via Akt/ nuclear factor-k B pathway. Am J Respir Crit Care Med 2011; 183:522-30.